• BIZENGRI^® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic¹
• Merus and Partner Therapeutics announced a license agreement for U.S. commercialization

Utrecht, The Netherlands, and Cambridge, Massachusetts Dec. 04, 2024 /Globe Newswire/ — Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics^® and Triclonics^®), announced today that the U.S. Food and ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., December 2, 2024– Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics^®) and Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company with a focus in hematology and oncology, today announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer ...